Gland Pharma: No Share Dematerialization/Rematerialization Requests for Q4FY26
Gland Pharma Limited confirmed no share dematerialization or rematerialization requests were received for the quarter ended March 31, 2026. This is in accordance with SEBI (Depositories and Participants) Regulations, 2018.
This is a standard regulatory filing confirming the absence of specific corporate actions related to share dematerialization/rematerialization. It does not introduce new business developments or financial information that would significantly impact the company's valuation or operations.
The announcement is a routine compliance filing and does not contain any information that would positively or negatively impact the company's stock or business operations.
Gland Pharma Limited has submitted a confirmation certificate for the quarter ended March 31, 2026, as per Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, received from the Registrar and Share Transfer Agent, MUFG Intime India Private Limited (formerly Link Intime India Private Limited), confirms that no requests for dematerialization or rematerialization of equity shares were received during the specified period.
This submission is for the information and records of the stock exchanges. The company has provided its registered office and corporate office details, along with contact information and CIN.
The Registrar and Share Transfer Agent, MUFG Intime India Private Limited, has also issued a confirmation stating that no requests for dematerialization or rematerialization of equity shares were processed for Gland Pharma Limited during the quarter ended March 31, 2026, as per the SEBI regulations.
What to do with a filing like this
Gland Pharma Limited filed this with the NSE as a statutory disclosure, categorised under sebi compliance filings. It is a primary document, not a recommendation, and the desk marks it low impact, the band that almost never moves a portfolio on its own.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Gland Pharma Limited. Read the original for the full detail.